Our Portfolio

The Alzheimer's Drug Discovery Foundation (ADDF) publishes all programs that we fund in our research portfolio. Funded research projects can be viewed by the year of funding or by program area, and can also be found by searching for an investigator or certain keywords. Please note that your search term(s) must contain at least four characters.

Additionally, please note that grant funding priorities at the ADDF change over time. The ADDF maintains strict confidentiality with all of our funded projects and cannot share additional information on projects without permission from the investigator(s).

The ADDF does not recommend one particular clinical trial or research program over another. The ADDF is not responsible for the accuracy of the information provided, the selection of research subjects (patients) or the conduct of the clinical trial, treatment IND/expanded access program or other research program.

SEARCH GRANTS

Your grant search has return( 606 ) results

Page 1 of 61

Toggle Program

- Year
- Grantee
- Organization
- Title
- Program Area
- Amount

Toggle
- 2019
- Laura Ibanez, PhD
- Washington University School of Medicine in St. Louis
- Plasma Cell-Free RNA as Alzheimer's Disease non-invasive biomarker
- Biochemical Biomarkers (Blood, Other
- $281,370
Duration: 11/15/2019 - 11/15/2021

Abstract:

This project measures gene products in the blood (called cell-free ribonucleic acid (cfRNA)) associated with Alzheimer’s disease. This type of test has revolutionized prenatal screening and cancer prognosis. A set of 25 gene products identified from a small number of Alzheimer’s patients will be assessed in a larger, well characterized population to create, optimize, and evaluate a predictive disease model. This research will enable the generation of a novel, non-invasive test that can predict disease onset. This in turn will help with correct diagnosis, appropriate clinical trial design for intervention and disease monitoring.

Toggle
- 2019
- Eliav Shaked, MSc
- RetiSpec Inc.
- Retinal Changes in AD Correlated with Cerebral Amyloid Staging, A Promising Early Biomarker in AD
- Abeta
- $500,000
Duration: 09/13/2019 - 09/13/2021

Abstract:

RetiSpec is harnessing retinal hyperspectral imaging to allow for the accurate, rapid and cost-effective identification of the signs of Alzheimer’s disease years before a patient presents clinical symptoms. In a pilot human study, the non-invasive retinal imaging technology was effective in detecting small changes in biomarkers associated with the pathological signs of Alzheimer’s, including the aggregation of soluble amyloid-beta. To validate the use of the technology in patients, RetiSpec is collaborating with the Toronto Memory Program, Canada's largest Alzheimer's clinical trial site, and The Joseph Sagol Neuroscience Center at Sheba Medical Center, Israel.

Toggle
- 2019
- Samuil Umansky, MD, PhD
- DiamiR Biosciences
- Circulating brain-enriched microRNAs as peripheral biomarkers of neurodegeneration.
- Biochemical Biomarkers (Blood
- $492,000
Duration: 11/11/2019 - 11/10/2020

Abstract:

DiamiR Biosciences is developing a targeted diagnostic test to measure specific microRNAs, small molecules that regulate gene expression and reflect multiple cellular processes in blood. The molecules identified by DiamiR are associated with neurodegeneration and inflammation – two integral components of Alzheimer’s disease. They have evidence that these biomarkers can indicate Alzheimer’s disease prior to symptom onset.

Toggle
- 2019
- Douglas Galasko, MD
- University of California, San Diego
- TABLOOD: a biomarker panel for direct assessment in blood of AD pathophysiological hallmarks.
- Biochemical Biomarkers (Blood, Tau
- $375,000
Duration: 08/01/2019 - 01/31/2021

Abstract:

Neurofibrillary tangles, consisting of the tau protein, represent one of the two major pathological hallmarks of Alzheimer’s disease. This project aims to develop a test for Alzheimer's disease by measuring tau and NfL, a protein indicative of neurodegeneration, in the blood. Dr. Galasko and his collaborators at ADx Neurosciences are developing these tests using a highly sensitive technology called single molecule immunoassay, which can detect proteins at very low concentrations in blood. These tests will pave the way for early disease diagnosis.

Toggle
- 2019
- Rodney Pearlman, PhD
- Bluefield Project to Cure FTD
- Remote blood biomarker monitoring in frontotemporal lobar degeneration: Neurofilament Surveillance
- Biochemical Biomarkers (Blood
- $1,200,000
Duration: 10/01/2019 - 07/30/2024

Abstract:

Dr. Pearlman and the Bluefield team will evaluate blood neurofilament light chain (NfL) levels in people that carry an inherited form of frontotemporal degeneration (FTD), but do not yet show any disease symptoms. NfL is a protein in neurons that is released when the neurons are injured. The success of this test will support more efficient clinical trials, which could lead to effective treatments for FTD.

Toggle
- 2019
- Henrik Zetterberg, MD
- University of Gothenburg
- Fully automated plasma assays as screening tests for Alzheimer-related amyloid β pathology
- Biochemical Biomarkers (Blood, Abeta
- $3,197,896
Duration: 11/11/2019 - 11/10/2022

Abstract:

Dr. Zetterberg and his lab are developing a test to detect Aβ40 and Aβ42 protein fragments in blood samples in a collaboration with Roche Diagnostics. Excess amounts of these proteins aggregate to form amyloid plaques, one of the hallmark pathological signs of Alzheimer’s disease. This blood test is one of the most advanced blood tests in development for the diagnosis for Alzheimer’s disease.

Toggle
- 2019
- Peter van Wijngaarden, PhD
- Centre for Eye Research Australia
- A non-invasive retinal biomarker as a screening test for Alzheimer’s disease
- Abeta
- $420,321
Duration: 08/15/2019 - 08/15/2021

Abstract:

Dr. van Wijngaarden's study will test a simplified eye scan, which can detect amyloid in the retina prior to signs of cognitive decline. The team is developing a more portable and inexpensive prototype camera. The study will establish whether this novel eye imaging technique can replace expensive PET imaging or invasive CSF tests for Alzheimer's diagnosis and be used to detect early signs of Alzheimer's prior to signs of cognitive decline.

Toggle
- 2019
- Tom MacGillivray, PhD
- University of Edinburgh
- Delivering novel neuro-retinal biomarkers for the early diagnosis of Alzheimer’s disease
- Other
- $488,997
Duration: 08/01/2019 - 01/31/2021

Abstract:

This study employs a novel combination of retinal biomarkers capturing neurodegeneration and vasculature dysfunction often found in Alzheimer's disease with advanced imaging analyses. The results of this project, if successful, may be offered for widespread use as a cloud-based system for analyzing retinal images or incorporated into the eye scan device software.

Toggle
- 2019
- Kaj Blennow, MD, PhD
- University of Gothenburg
- Brain-specific tau in blood as an Alzheimer Diagnostic Accelerator
- Biochemical Biomarkers (Blood, Tau
- $500,000
Duration: 09/01/2019 - 09/01/2021

Abstract:

Dr. Blennow's team is developing the first ultra-sensitive blood test for brain-specific tau. His team has identified brain-derived tau fragments in the cerebral spinal fluid that correlate well with Alzheimer’s disease neuropathology and will now extend this unique approach into blood.

Toggle
- 2019
- Saliha Moussaoui, PhD
- Amoneta Diagnostics SAS, France
- Validation of a rapid non-invasive diagnostic test to predict mild cognitive impairment and early AD
- Biochemical Biomarkers (Blood, Other
- $2,000,000
Duration: 03/29/2019 - 09/29/2019

Abstract:

Amoneta is developing a rapid non-invasive diagnostic test to predict mild cognitive impairment (MCI) and early Alzheimer's disease (in support of the MemoryLINC project). The proposed test panel measures two species of ribonucleic acids that are stable in the blood and show promise in early detection of Alzheimer's disease.

Page 1 of 61